Daré Bioscience (DARE) Stock Overview
Develops therapies in the areas of contraception, pelvic pain, fertility, infectious disease, menopause, and sexual and vaginal health in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
DARE Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Daré Bioscience, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.99 |
| 52 Week High | US$9.19 |
| 52 Week Low | US$1.61 |
| Beta | 0.78 |
| 1 Month Change | 11.80% |
| 3 Month Change | -13.10% |
| 1 Year Change | -41.12% |
| 3 Year Change | -85.06% |
| 5 Year Change | -87.62% |
| Change since IPO | -97.24% |
Recent News & Updates
Recent updates
We're A Little Worried About Daré Bioscience's (NASDAQ:DARE) Cash Burn Rate
Nov 07
We Think Daré Bioscience (NASDAQ:DARE) Needs To Drive Business Growth Carefully
Jul 21Is Daré Bioscience (NASDAQ:DARE) In A Good Position To Invest In Growth?
Mar 12Daré rises on positive data from early-to-mid-stage trial of intravaginal ring to treat menopause symptoms
Oct 17Daré Bioscience rises as company submits application to begin trial of non-hormonal contraceptive
Oct 10Dare Bioscience reports positive progress for cream for female sexual arousal disorder
Aug 29Daré Bioscience signs agreement with Organon for bacterial vaginosis therapy
Jun 30Will Daré Bioscience (NASDAQ:DARE) Spend Its Cash Wisely?
Apr 02Diving Back Into Daré Bioscience Again
Jan 07We Think Daré Bioscience (NASDAQ:DARE) Needs To Drive Business Growth Carefully
Nov 26Why Daré Bioscience, Inc. (NASDAQ:DARE) Could Be Worth Watching
Dec 22
Shareholder Returns
| DARE | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 1.5% | -1.7% | 0.5% |
| 1Y | -41.1% | 23.6% | 16.6% |
Return vs Industry: DARE underperformed the US Pharmaceuticals industry which returned 23.6% over the past year.
Return vs Market: DARE underperformed the US Market which returned 16.6% over the past year.
Price Volatility
| DARE volatility | |
|---|---|
| DARE Average Weekly Movement | 9.6% |
| Pharmaceuticals Industry Average Movement | 10.0% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: DARE has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: DARE's weekly volatility (10%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 22 | Sabrina Johnson | darebioscience.com |
Daré Bioscience, Inc. develops therapies in the areas of contraception, pelvic pain, fertility, infectious disease, menopause, and sexual and vaginal health in the United States. The company offers XACIATO, a lincosamide antibacterial gel for the treatment of bacterial vaginosis. It also develops Ovaprene, a hormone-free monthly intravaginal contraceptive; Sildenafil Cream, a cream formulation of sildenafil for topical administration to the female genitalia for the treatment of female sexual arousal disorder; DARE-HRT1 to treat vasomotor symptoms in menopausal hormone therapy; DARE-VVA1 for the treatment of dyspareunia or pain during sexual intercourse; and DARE-HPV, a fixed-dose formulation of lopinavir and ritonavir in a soft gel vaginal insert to treat genital human papillomavirus (HPV) infection, cervical intraepithelial neoplasia, and other HPV-related pathologies.
Daré Bioscience, Inc. Fundamentals Summary
| DARE fundamental statistics | |
|---|---|
| Market cap | US$28.44m |
| Earnings (TTM) | -US$17.46m |
| Revenue (TTM) | n/a |
Is DARE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| DARE income statement (TTM) | |
|---|---|
| Revenue | -US$57.13k |
| Cost of Revenue | US$14.30m |
| Gross Profit | -US$14.35m |
| Other Expenses | US$3.11m |
| Earnings | -US$17.46m |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.22 |
| Gross Margin | 25,126.32% |
| Net Profit Margin | 30,568.80% |
| Debt/Equity Ratio | 0% |
How did DARE perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/01/06 19:27 |
| End of Day Share Price | 2026/01/05 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Daré Bioscience, Inc. is covered by 7 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Kumaraguru Raja | Brookline Capital Markets |
| Brian Kemp Dolliver | Brookline Capital Markets |
| Douglas Tsao | H.C. Wainwright & Co. |